Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,364 recruiting studies in this area right now.
By phase
- Not applicable9,630
- Phase 24,440
- Phase 12,682
- Phase 1/Phase 21,657
- Phase 31,400
- Phase 2/Phase 3286
- Phase 4269
Top conditions
- Breast Cancer1,208
- Prostate Cancer651
- Cancer636
- Colorectal Cancer475
- Lung Cancer420
- Ovarian Cancer341
- Multiple Myeloma327
- Pancreatic Cancer289
- Gastric Cancer285
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma260
- Solid Tumor246
- Advanced Solid Tumor229
- Head and Neck Cancer228
- Cervical Cancer223
- Endometrial Cancer212
- Advanced Solid Tumors210
- Esophageal Cancer190
Leading sponsors
- M.D. Anderson Cancer Center460
- Fudan University306
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University276
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca133
- Ruijin Hospital130
Where studies are running
- California1,397
- Texas638
- Arizona504
- Florida440
- Alabama430
- New York404
- Massachusetts341
- Maryland329
- New Jersey275
- Pennsylvania234
Recruiting studies20,364 total
- NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04052048Recruiting
Active surveillance prostate cancer test registry study
This study enrolls men with low-risk prostate cancer who are either staying on active surveillance or planning surgery soon. It uses a new “SNEP assay” test to help monitor prostate cancer over time and may improve how doctors track risk.
Royal Oak, MichiganAges 40–80 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Duarte, CaliforniaAges 4 weeks+ - NCT04068155Recruiting
Radiation device for certain skin cancers you can treat locally
This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.
GrenobleAges 18 years+ - NCT04115761RecruitingPhase 2
ADCv01 added to standard care for newly diagnosed glioblastoma
This Phase 2 study tests ADCV01, given “on top of” other standard treatment, for newly diagnosed glioblastoma (grade 4 brain tumor). The goal is to see whether it helps patients live longer and safely manage tumor growth.
Taichung, Non-USAges 20–75 - NCT04055220Recruiting
Regorafenib to keep bone cancer from coming back
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
BesançonAges 12 years+ - NCT04140487RecruitingPhase 1/Phase 2
Study drugs for certain FLT3-mutated blood cancers that have returned
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
Houston, TexasAges 18 years+ - NCT04084730RecruitingPhase 2
3-day radiation after breast-conserving surgery for certain breast cancers
This trial tests whether a shorter, 3-day course of partial breast radiation after surgery works as well as standard radiation for women with early-stage breast cancer. It may help reduce time in treatment while aiming to keep cancer from coming back in the treated breast area.
Norwalk, ConnecticutAges 45 years+ - NCT04134559RecruitingPhase 2
Pembrolizumab for kids with liver cancer that came back
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
San Francisco, CaliforniaAges birth–30 years - NCT04099797RecruitingPhase 1
CAR T therapy for certain GD2 brain tumors
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Houston, TexasAges 1–25 - NCT04094454Recruiting
Vaginal dilation during pelvic radiation for anal cancer
This trial studies a method to make vaginal dilation easier during pelvic radiotherapy in women with anal cancer. It may help reduce or prevent treatment-related vaginal narrowing and improve comfort and function.
HeidelbergAges 18 years+ - NCT04053855Recruiting
Check urine for kidney cancer signals before or after surgery
This study looks for tiny substances in urine (called exosomes) to see if they can help identify clear cell kidney cancer. It compares urine samples from people having planned kidney surgery with people having surgery without a scheduled plan.
Saint-EtienneAges 18 years+ - NCT04040205RecruitingPhase 2
Abemaciclib for sarcoma with specific cell-growth gene changes
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
Jacksonville, FloridaAges 18 years+ - NCT04083495RecruitingPhase 2
CAR T treatment for relapsed CD30-positive T-cell lymphoma
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Chapel Hill, North CarolinaAges 18–99 - NCT04098471Recruiting
Comparing two rectal cancer surgeries for T2 tumors
This trial compares two different surgery approaches for early-stage rectal cancer (T2N0M0) that is close to the anus. It tests whether a less invasive local removal followed by radiation works as well as more extensive surgery (total mesorectal excision).
Nanjing, JiangsuAges 18–75 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04109079Recruiting
Best surgery plan for breast cancer lymph nodes after chemotherapy
This study looks at the safest and most useful way to remove and check breast-cancer lymph nodes in the armpit after you finish chemotherapy given before surgery. It may help you avoid unnecessary surgery while still getting accurate information about how well the treatment worked.
DublinAges 18 years+ - NCT04082520RecruitingPhase 2
Lutathera for non-surgery meningioma that keeps growing
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
Rochester, MinnesotaAges 18 years+ - NCT04107181Recruiting
Speculum-free screening for cervical cancer testing
This pilot study tests a new way to check for cervical cancer that does not use a speculum (a tool used during pelvic exams). If you qualify, you may be offered this alternative screening method as part of the study.
Durham, North CarolinaAges 21–65 - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT04083183RecruitingPhase 1/Phase 2
Testing radiation plus antibody therapy for certain non-cancer diseases
This early-phase study tests a conditioning treatment using total-body irradiation and a radioactive antibody (called astatine-211) before a stem cell transplant for non-cancer conditions. The goal is to improve how well the donor cells take hold and are tolerated.
Seattle, WashingtonAges 18–49
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,364 recruiting oncology studies from the U.S. registry right now, out of 31,668 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.